Drug Profile
Brefeldin A - Aphios
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Aphios Corporation
- Class Cytostatic antibiotics; Macrolides
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Cancer in USA (IV)
- 12 Jul 2016 Early research in Cancer in USA (IV)